Site icon The Rojak Pot

2-in-1 Omicron Vaccines From Pfizer + Moderna Are Coming!

Both Pfizer and Moderna have successfully tested their 2-in-1 COVID-19 vaccines which offer significantly better protection against Omicron and its sub variants!


2-in-1 Omicron Vaccines From Pfizer + Moderna Are Coming!

Pfizer and Moderna announced, on 25 June and 8 June respectively, that they successfully tested their bivalent COVID-19 vaccines.

The Moderna bivalent COVID-19 vaccine targets both the original SARS-CoV-2 strain, as well as the current Omicron variant. Moderna says it’s their lead candidate for the Fall 2022 booster dose.

Pfizer tested both a bivalent COVID-19 vaccine, as well as a monovalent vaccine that targets the Omicron variant, in two dose levels – the “regular” 30 µg, and a higher 60 µg.

All three mRNA vaccine candidates offered significantly higher neutralising antibody titres against the Omicron variant.

The US FDA and other health regulators are now looking into whether to offer them as a booster dose for the fall season.


Pfizer + Moderna Omicron COVID Vaccines : What We Know So Far…

Moderna Bivalent COVID-19 Vaccine

Designed as a booster dose, the Moderna bivalent COVID-19 vaccine contains the original mRNA-1273 (Spikevax) vaccine and a vaccine candidate targeting the Omicron variant.

The resulting mRNA-1273.214 mix was tested at the standard 50 µg dose, and found to increase the geometric mean title (GMT) against Omicron by approximately 8X above the baseline level (without the booster dose).

Antibody levels dropped after a month, but the new mRNA-1273.214 vaccine candidate still showed significantly higher antibody levels against the Omicron variant, compared to the original Spikevax vaccine.

GMT Levels
(after 1 month)
Ancestral SARS-CoV-2 5977 5649 +5.8%
Omicron Variant 2372 1473 +61.0%

Moderna also said that the new bivalent vaccine candidate has a similar safety profile to its original Spikevax vaccine, when both vaccines were administered as a second booster dose.

Pfizer Bivalent + Monovalent COVID-19 Vaccines

Pfizer and BioNTech tested both an Omicron-specific monovalent vaccine, as well as a bivalent mix like Moderna. They also tested them in both the standard 30 µg dose, and a higher 60 µg dose.

The Omicron-only booster dose offered the strongest immune response against the Omicron variant – 2X to 3X higher than the original COMIRNATY vaccine.

Their bivalent booster dose candidate, on the other hand, offered 1.5X to 2X higher antibody levels against the Omicro variant than the original COMIRNATY vaccine.

However, health authorities are likely to prefer the bivalent version as it will boost protection against the original virus, as well as the Omicron variant at the same time.

Pfizer Vaccine Type GMR
(vs. Omicron)
60 µg Monovalent 3.15
30 µg Monovalent 2.23
60 µg Bivalent 1.97
30 µg Bivalent 1.56
30 µg Original Vaccine Baseline

One month after administration, both monovalent and bivalent Pfizer vaccine candidates offered significantly higher neutralising antibodies against the Omicron BA.1 variant.

Pfizer Vaccine Type GMT
(vs. Omicron)
60 µg Monovalent 19.6X
30 µg Monovalent 13.5X
60 µg Bivalent 10.9X
30 µg Bivalent 9.1X
Without Booster Baseline

Pfizer also Said that both vaccine candidates demonstrated a favourable safety and tolerability profile, similar to the original Pfizer-BioNTech COVID-19 vaccine.


Please Support My Work!

Support my work through a bank transfer /  PayPal / credit card!

Name : Adrian Wong
Bank Transfer : CIMB 7064555917 (Swift Code : CIBBMYKL)
Credit Card / Paypal :

Dr. Adrian Wong has been writing about tech and science since 1997, even publishing a book with Prentice Hall called Breaking Through The BIOS Barrier (ISBN 978-0131455368) while in medical school.

He continues to devote countless hours every day writing about tech, medicine and science, in his pursuit of facts in a post-truth world.


Recommended Reading


Support Us!

If you like our work, please support us by visiting our sponsors, or donating to our fund. Thank you!

Exit mobile version